A Phase 1 First-in-Human Study of the MCL-1 Inhibitor AZD5991 in Patients with Relapsed/Refractory Hematologic Malignancies.
Desai P, Lonial S, Cashen A, Kamdar M, Flinn I, O'Brien S, Garcia JS, Korde N, Moslehi J, Wey M, Cheung P, Sharma S, Olabode D, Chen H, Ali Syed F, Liu M, Saeh J, Andrade-Campos M, Kadia TM, Blachly JS.
Desai P, et al. Among authors: korde n.
Clin Cancer Res. 2024 Nov 1;30(21):4844-4855. doi: 10.1158/1078-0432.CCR-24-0028.
Clin Cancer Res. 2024.
PMID: 39167622
Free PMC article.
Clinical Trial.